ArticlePloS one2026
Associations between area-level socioeconomic disadvantage and COVID-19 disease consequences in Sydney, Australia: A retrospective cohort analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSocioeconomic disparities have shaped COVID-19 outcomes worldwide. Focusing on disease consequences once infected (severity among cases), we examined whether area-level socioeconomic disadvantage was associated with hospitalisation and death among COVID-19 cases in Greater Sydney, Australia.
methodsWe conducted a retrospective cohort study of confirmed and probable COVID-19 cases recorded in the New South Wales Notifiable Conditions Information Management System from 2 March 2020-21 February 2022. Area-level disadvantage was measured using the Index of Relative Socio Economic Disadvantage (IRSD). We modelled the odds of (a) hospitalisation and (b) death conditional on infection using logistic regression, adjusting for age, gender and pandemic phase.
resultsAmong 782,883 included cases, 3.5% were hospitalised and 0.2% died due to COVID-19. After adjustment, a 100-point increase in IRSD score (indicating less socioeconomic disadvantage) was significantly associated with lower odds of hospitalisation (adjusted odds ratio [AOR] 0.80, 95% CI 0.79-0.81) and death (AOR 0.78, 95% CI 0.74-0.83). There was no evidence that these associations differed across pandemic phases.
conclusionsArea‑level socioeconomic disadvantage was associated with higher risks of hospitalisation and death among COVID‑19 cases in Greater Sydney - a setting with public hospital care - with some postal areas having more than twice the odds of hospitalisation and death as others. Given the absence of linked comorbidity and vaccination data, the most plausible explanation is disparities in comorbidity and risk‑factor burden, although contributions from differences in access to testing and quality of care cannot be ruled out. Public health responses should prioritise chronic disease prevention and management in disadvantaged communities to mitigate inequitable outcomes in future pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.